Day One Biopharmaceuticals (DAWN.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov24

Day One Biopharmaceuticals Inc. Announces Three-Year Follow-Up Data for OJEMDA™ in Children's Low-Grade Glioma Phase II FIREFLY-1 Trial

13:00

Nov18

Day One Biopharmaceuticals Inc. to Participate in Piper Sandler's 37th Annual Healthcare Conference

13:30

Nov13

Day One Biopharmaceuticals Announces Acquisition of Mersana Therapeutics

11:00

Nov10

Day One Biopharmaceuticals to Present New Data on OJEMDA at Society Meeting

12:02

Nov5

Day One Biopharmaceuticals Receives Strong Buy Recommendation from Analyst

16:24

Day One Biopharmaceuticals released FY2025 9 Months Earnings on November 4 After-Market EST, with actual revenue of USD 104.46 M and EPS of USD -0.8354

00:00

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 39.8 M, Net Income -19.73 M, EPS -0.1908

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 33.91 M, Net Income -30.32 M, EPS -0.2941

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 30.76 M, Net Income -36 M, EPS -0.3504

View More

Rivian: Narrowing Losses, R2 Mass Production Imminent, Is Rivian's Dawn Approaching?

11-05 10:59

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More